Who
Lauren P. Silvernail
Director
Company insider
Files Form 4 as: Director, Harrow; Director, Dynavax Technologies; Director, Harpoon Therapeutics; Officer, Evolus; CFO & Cbo, Revance Therapeutics; CFO & VP Corporate Development, Ista Pharmaceuticals.
In numbers
- Trades disclosed
- 170
- Buys
- 4
- Sells
- 15
- Bought
- $101K
- Sold
- $3.7M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 16 Feb 2006
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $31K1,000 at $31.00 | filing |
| 18 May 2026filed 19 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $31K1,000 at $31.00 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax TechnologiesBiotechnology | SEC FORM 4 Code D | —10,075 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,750 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,125 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —42,750 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —7,125 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologies | SEC FORM 4 Code D | —10,075 | filing |
| 20 Jun 2025filed 24 Jun 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,339 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —7,125 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologies | SEC FORM 4 Code A | —1,439 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —8,636 | filing |
| 3 Feb 2025filed 5 Feb 2025 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —42,750 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —8,347 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,033 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,300 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeutics | SEC FORM 4 Code D | —5,000 | filing |
| 26 Jan 2024filed 30 Jan 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,119 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)HROW · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Lauren P. Silvernail; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.